In this respect, restoring A-SMase in melanomas by genetic overexpression or by recombinant protein administration, a protocol currently under examination for Niemann-Pick type B patients [53], might be considered a useful adjuvant for cancer therapy. The gene discussed is SMPD1; the disease is melanoma.